Bloomberg News

Richter, Forest Report Positive Phase III Cariprazine Result

October 05, 2011

Oct. 5 (Bloomberg) -- Gedeon Richter Nyrt., Hungary’s biggest drugmaker, and Forest Laboratories Inc. reported today “positive” results from a Phase III clinical trial of cariprazine, an antipsychotic agent.

Data showed that patients with acute manic episodes who were treated with cariprazine “experienced significant symptom improvement compared with placebo-treated patients,” the two companies said in a statement posted on the website of the Budapest Stock Exchange today.

--Editor: Alan Purkiss

To contact the reporter on this story: Andras Gergely in Budapest at agergely@bloomberg.net

To contact the editor responsible for this story: Gavin Serkin at gserkin@bloomberg.net


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus